1-8 of 8
Tina Albertson, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 593.
https://doi.org/10.1182/blood-2019-127150
Published: 2019
Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 241.
https://doi.org/10.1182/blood-2019-127508
Published: 2019
Journal Articles

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 581.
https://doi.org/10.1182/blood.V130.Suppl_1.581.581
Published: 2017
Journal Articles

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Tanya Siddiqi, MD, Jeremy S. Abramson, MD MMSc, Daniel Li, PhD, William Brown, MAS, Todd Devries, PhD, Kedar Dave, PhD, Jacob Garcia, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, BS, Andres Forero-Torres, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Claire L Sutherland, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 193.
https://doi.org/10.1182/blood.V130.Suppl_1.193.193
Published: 2017
Journal Articles

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Christina Swanson, PhD, Trevor Do, Samantha Merrigan, Shaparak Lonning, Kim Merriam, Joshua Prentiss, Janani Sridar, Claire L Sutherland, PhD, Benhuai Xie, PhD, Minh Pham, Daniel Li, PhD, Tina Albertson, MD, Howard M Stern, MDPhD, Sharon Moulis, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 194.
https://doi.org/10.1182/blood.V130.Suppl_1.194.194
Published: 2017
Journal Articles

JCAR017 Is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cell to Patients with NHL

Christopher G. Ramsborg, PhD, Paul Guptill, Clinton Weber, BS, Brian Christin, BS, Ryan P Larson, PhD, Kenneth Lewis, PhD, Mary Mallaney, Michael Bowen, PhD, Eileen Higham, PhD, Tina Albertson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4471.
https://doi.org/10.1182/blood.V130.Suppl_1.4471.4471
Published: 2017
Journal Articles

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Mark Heipel, BSc, Jeffrey Smith, BA, William Brown, MAS, Mandana Karimi, MSc, Benhuai Xie, PhD, Daniel Li, PhD, Tina Albertson, MD, Jacob Garcia, MD, Todd Devries, PhD, Claire L Sutherland, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2835.
https://doi.org/10.1182/blood.V130.Suppl_1.2835.2835
Published: 2017
Journal Articles

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David G. Maloney, MD PhD, Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1552.
https://doi.org/10.1182/blood.V130.Suppl_1.1552.1552
Published: 2017